Fluorescence molecular optomic signatures improve identification of tumors in head and neck specimens.
ABY-029
cancer detection
epidermal growth factor receptor
fluorescence molecular imaging
head and neck cancer
optomics
radiomic analysis
Journal
Frontiers in medical technology
ISSN: 2673-3129
Titre abrégé: Front Med Technol
Pays: Switzerland
ID NLM: 101772626
Informations de publication
Date de publication:
2023
2023
Historique:
received:
02
08
2022
accepted:
16
01
2023
entrez:
6
3
2023
pubmed:
7
3
2023
medline:
7
3
2023
Statut:
epublish
Résumé
Fluorescence molecular imaging using ABY-029, an epidermal growth factor receptor (EGFR)-targeted, synthetic Affibody peptide labeled with a near-infrared fluorophore, is under investigation for surgical guidance during head and neck squamous cell carcinoma (HNSCC) resection. However, tumor-to-normal tissue contrast is confounded by intrinsic physiological limitations of heterogeneous EGFR expression and non-specific agent uptake. In this preliminary study, radiomic analysis was applied to optical ABY-029 fluorescence image data for HNSCC tissue classification through an approach termed "optomics." Optomics was employed to improve tumor identification by leveraging textural pattern differences in EGFR expression conveyed by fluorescence. The study objective was to compare the performance of conventional fluorescence intensity thresholding and optomics for binary classification of malignant vs. non-malignant HNSCC tissues. Fluorescence image data collected through a Phase 0 clinical trial of ABY-029 involved a total of 20,073 sub-image patches (size of 1.8 × 1.8 mm Optomics provided consistent improvement in prediction accuracy and false positive rate (FPR) and similar false negative rate (FNR) on all testing set slices, irrespective of dose, compared to fluorescence intensity thresholding (mean accuracies of 89% vs. 81%, Optomics outperformed conventional fluorescence intensity thresholding for tumor identification using sub-image patches as the unit of analysis. Optomics mitigate diagnostic uncertainties introduced through physiological variability, imaging agent dose, and inter-specimen biases of fluorescence molecular imaging by probing textural image information. This preliminary study provides a proof-of-concept that applying radiomics to fluorescence molecular imaging data offers a promising image analysis technique for cancer detection in fluorescence-guided surgery.
Sections du résumé
Background
UNASSIGNED
Fluorescence molecular imaging using ABY-029, an epidermal growth factor receptor (EGFR)-targeted, synthetic Affibody peptide labeled with a near-infrared fluorophore, is under investigation for surgical guidance during head and neck squamous cell carcinoma (HNSCC) resection. However, tumor-to-normal tissue contrast is confounded by intrinsic physiological limitations of heterogeneous EGFR expression and non-specific agent uptake.
Objective
UNASSIGNED
In this preliminary study, radiomic analysis was applied to optical ABY-029 fluorescence image data for HNSCC tissue classification through an approach termed "optomics." Optomics was employed to improve tumor identification by leveraging textural pattern differences in EGFR expression conveyed by fluorescence. The study objective was to compare the performance of conventional fluorescence intensity thresholding and optomics for binary classification of malignant vs. non-malignant HNSCC tissues.
Materials and Methods
UNASSIGNED
Fluorescence image data collected through a Phase 0 clinical trial of ABY-029 involved a total of 20,073 sub-image patches (size of 1.8 × 1.8 mm
Results
UNASSIGNED
Optomics provided consistent improvement in prediction accuracy and false positive rate (FPR) and similar false negative rate (FNR) on all testing set slices, irrespective of dose, compared to fluorescence intensity thresholding (mean accuracies of 89% vs. 81%,
Conclusions
UNASSIGNED
Optomics outperformed conventional fluorescence intensity thresholding for tumor identification using sub-image patches as the unit of analysis. Optomics mitigate diagnostic uncertainties introduced through physiological variability, imaging agent dose, and inter-specimen biases of fluorescence molecular imaging by probing textural image information. This preliminary study provides a proof-of-concept that applying radiomics to fluorescence molecular imaging data offers a promising image analysis technique for cancer detection in fluorescence-guided surgery.
Identifiants
pubmed: 36875185
doi: 10.3389/fmedt.2023.1009638
pmc: PMC9975724
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1009638Informations de copyright
© 2023 Chen, Streeter, Hunt, Sardar, Gunn, Tafe, Paydarfar, Pogue, Paulsen and Samkoe.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cancer Res. 2006 Aug 1;66(15):7630-8
pubmed: 16885363
Ann Surg Oncol. 2009 Oct;16(10):2943-52
pubmed: 19582506
Radiology. 2016 Feb;278(2):563-77
pubmed: 26579733
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Nat Rev Cancer. 2018 Aug;18(8):500-510
pubmed: 29777175
Sci Rep. 2021 Nov 8;11(1):21832
pubmed: 34750471
Ann Transl Med. 2021 May;9(9):825
pubmed: 34268438
Mol Oncol. 2018 Jan;12(1):3-20
pubmed: 29124875
Mol Imaging Biol. 2017 Aug;19(4):610-616
pubmed: 27830425
Mol Imaging Biol. 2023 Feb;25(1):110-121
pubmed: 34651290
Proc SPIE Int Soc Opt Eng. 2013 Feb 26;8584:
pubmed: 25285190
Theranostics. 2021 May 21;11(15):7130-7143
pubmed: 34158840
Mol Imaging Biol. 2020 Feb;22(1):156-164
pubmed: 31054001
J Control Release. 2000 Mar 1;65(1-2):271-84
pubmed: 10699287
Cancer Res. 2018 Sep 1;78(17):5144-5154
pubmed: 29967260
Theranostics. 2018 Mar 28;8(9):2488-2495
pubmed: 29721094
Sci Rep. 2015 Aug 17;5:13087
pubmed: 26278466
Clin Cancer Res. 2007 Jun 15;13(12):3449-59
pubmed: 17575207
Biomed Opt Express. 2015 Sep 03;6(10):3765-82
pubmed: 26504628
Cancer Res. 2014 Dec 15;74(24):7465-74
pubmed: 25344226
Cancer Res. 1993 Aug 1;53(15):3579-84
pubmed: 8339264
Oral Oncol. 2019 Jan;88:58-65
pubmed: 30616798
J Thorac Imaging. 2018 Jan;33(1):26-34
pubmed: 28346329
Laryngoscope. 2022 Jan;132(1):36-44
pubmed: 34633092
Mol Imaging Biol. 2017 Aug;19(4):512-521
pubmed: 27909986
Front Oncol. 2017 Dec 22;7:314
pubmed: 29312886
Cell Mol Life Sci. 2008 May;65(10):1566-84
pubmed: 18259690
Cancers (Basel). 2021 Jul 13;13(14):
pubmed: 34298721
Radiat Oncol. 2006 May 02;1:11
pubmed: 16722544
Chem Biol Interact. 2005 May 30;153-154:123-7
pubmed: 15935808
Nat Commun. 2020 Nov 9;11(1):5667
pubmed: 33168818
Radiology. 2020 May;295(2):328-338
pubmed: 32154773
Mol Imaging Biol. 2014 Jun;16(3):372-82
pubmed: 24217944
Proc Natl Acad Sci U S A. 2013 May 28;110(22):9025-30
pubmed: 23671066
Magn Reson Med. 2009 Aug;62(2):488-99
pubmed: 19466747
Magn Reson Imaging. 2012 Nov;30(9):1234-48
pubmed: 22898692
Front Oncol. 2020 Jan 10;9:1476
pubmed: 31998640
Nat Rev Clin Oncol. 2013 Sep;10(9):507-18
pubmed: 23881033
Clin Cancer Res. 2019 Aug 1;25(15):4656-4662
pubmed: 31142505
Clin Cancer Res. 2015 Aug 15;21(16):3658-66
pubmed: 25904751
J Photochem Photobiol B. 2010 Jan 21;98(1):77-94
pubmed: 20031443
Cancer Metastasis Rev. 2014 Sep;33(2-3):809-22
pubmed: 24913898
Nat Biomed Eng. 2020 Mar;4(3):259-271
pubmed: 31873212
Proc SPIE Int Soc Opt Eng. 2019 Feb;10862:
pubmed: 31595101
Cancer Res. 2017 Nov 1;77(21):e104-e107
pubmed: 29092951
Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232
pubmed: 7612182
Eur J Cancer. 2012 Mar;48(4):441-6
pubmed: 22257792
Phys Med Biol. 2015 Jul 21;60(14):5471-96
pubmed: 26119045
Nat Rev Cancer. 2013 Sep;13(9):653-62
pubmed: 23924645
Theranostics. 2020 Mar 4;10(9):3994-4005
pubmed: 32226534
Nat Commun. 2014 Jun 03;5:4006
pubmed: 24892406
Ann Surg Oncol. 2012 Nov;19(12):3879-87
pubmed: 22669455
Eur Radiol. 2020 Nov;30(11):6241-6250
pubmed: 32483644
Mol Imaging Biol. 2012 Oct;14(5):584-92
pubmed: 22203241
J Biomed Opt. 2012 Jun;17(6):066001
pubmed: 22734757
Magn Reson Med. 2003 Jul;50(1):92-8
pubmed: 12815683
Br J Oral Maxillofac Surg. 2003 Aug;41(4):224-31
pubmed: 12946663
Ann N Y Acad Sci. 2008;1130:35-43
pubmed: 18596329
Nature. 2000 Sep 14;407(6801):249-57
pubmed: 11001068
Biomed Opt Express. 2016 Aug 09;7(9):3280-3288
pubmed: 27699098
Nat Med. 2014 Nov;20(11):1348-53
pubmed: 25344739
Anal Chem. 2010 Mar 1;82(5):2129-33
pubmed: 20136134